| Jennifer Ruth Christenson, DO | |
|
1900 Woodland Dr, Coos Bay, OR 97420-2099 | |
| (541) 267-5151 | |
| (407) 425-5203 |
| Full Name | Jennifer Ruth Christenson |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 6 Years |
| Location | 1900 Woodland Dr, Coos Bay, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801156161 | NPI | - | NPPES |
| 500721760 | Medicaid | OR |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bay Area Hospital | Coos bay, OR | Hospital |
| Curry General Hospital | Gold beach, OR | Hospital |
| Southern Coos Hospital & Health Center | Bandon, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Bend Medical Center Inc | 5597677716 | 83 |
News Archive
BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.
The U.S. Food and Drug Administration today announced it has issued an emergency use authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.
Type 2 diabetes - the most common type of diabetes - triples the risk of an early menopause in women younger than 45 years of age, according to new research published in the peer-reviewed journal Climacteric.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
› Verified 3 days ago
| Entity Name | North Bend Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407812365 PECOS PAC ID: 5597677716 Enrollment ID: O20031105000138 |
News Archive
BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.
The U.S. Food and Drug Administration today announced it has issued an emergency use authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.
Type 2 diabetes - the most common type of diabetes - triples the risk of an early menopause in women younger than 45 years of age, according to new research published in the peer-reviewed journal Climacteric.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Ruth Christenson, DO 1900 Woodland Dr, Coos Bay, OR 97420-2099 Ph: (541) 267-5151 | Jennifer Ruth Christenson, DO 1900 Woodland Dr, Coos Bay, OR 97420-2099 Ph: (541) 267-5151 |
News Archive
BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.
ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.
The U.S. Food and Drug Administration today announced it has issued an emergency use authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.
Type 2 diabetes - the most common type of diabetes - triples the risk of an early menopause in women younger than 45 years of age, according to new research published in the peer-reviewed journal Climacteric.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
› Verified 3 days ago
Dr. Steven George Shimotakahara, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 Fax: 541-266-4513 | |
Mr. Charles Gerard Hurbis, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2695 N 17th St, Coos Bay, OR 97420 Phone: 541-266-0900 Fax: 541-266-0800 |